Respiri Limited Logo

Respiri Limited

RSH.AX

(1.0)
Stock Price

0,07 AUD

-120.11% ROA

-241.47% ROE

-6.31x PER

Market Cap.

51.638.754,00 AUD

2.24% DER

0% Yield

-1627.49% NPM

Respiri Limited Stock Analysis

Respiri Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Respiri Limited Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (6%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

3 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

4 ROE

Negative ROE (-116.77%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-146.86%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 PBV

The stock's high Price-to-Book Value (P/BV) ratio (7.75x) suggests it's overvalued, potentially making it an expensive investment.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Respiri Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Respiri Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Respiri Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Respiri Limited Revenue
Year Revenue Growth
1997 1.741.899
1998 0 0%
1999 0 0%
2000 0 0%
2001 49.000 100%
2002 51.000 3.92%
2003 392.719 87.01%
2004 0 0%
2005 51.911 100%
2006 33.571 -54.63%
2007 325.944 89.7%
2008 100.191 -225.32%
2009 225.432 55.56%
2010 348.493 35.31%
2011 332.087 -4.94%
2012 12.968 -2460.82%
2013 10.859 -19.42%
2014 18.975 42.77%
2015 93.988 79.81%
2016 677.755 86.13%
2017 825.603 17.91%
2018 861.455 4.16%
2019 1.026.252 16.06%
2020 0 0%
2020 2.155.307 100%
2021 270.074 -698.04%
2022 253.688 -6.46%
2023 70.533 -259.67%
2024 1.237.864 94.3%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Respiri Limited Research and Development Expenses
Year Research and Development Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 2.494.265 100%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1.319.467 100%
2008 3.021.130 56.33%
2009 2.026.361 -49.09%
2010 1.450.373 -39.71%
2011 1.404.785 -3.25%
2012 1.518.115 7.47%
2013 2.155.693 29.58%
2014 3.841.215 43.88%
2015 3.054.345 -25.76%
2016 1.310.723 -133.03%
2017 1.124.865 -16.52%
2018 1.512.288 25.62%
2019 4.237.397 64.31%
2020 2.035.426 -108.18%
2020 2.035.426 0%
2021 1.387.084 -46.74%
2022 1.463.343 5.21%
2023 377.725 -287.41%
2024 269.468 -40.17%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Respiri Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 5.192.000 100%
2003 1.209.951 -329.11%
2004 95.555 -1166.24%
2005 151.945 37.11%
2006 252.386 39.8%
2007 345.236 26.89%
2008 5.010.669 93.11%
2009 3.410.996 -46.9%
2010 2.716.504 -25.57%
2011 3.202.316 15.17%
2012 2.822.414 -13.46%
2013 2.119.922 -33.14%
2014 1.935.181 -9.55%
2015 461.183 -319.61%
2016 544.686 15.33%
2017 1.044.156 47.83%
2018 1.904.431 45.17%
2019 3.418.227 44.29%
2020 5.908.162 42.14%
2020 5.908.162 0%
2021 1.583.312 -273.15%
2022 1.148.163 -37.9%
2023 1.339.784 14.3%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Respiri Limited EBITDA
Year EBITDA Growth
1997 1.741.899
1998 -714.429 343.82%
1999 -1.796.835 60.24%
2000 -5.847.000 69.27%
2001 -8.664.000 32.51%
2002 -11.548.000 24.97%
2003 -3.954.222 -192.04%
2004 -833.906 -374.18%
2005 -690.269 -20.81%
2006 -199.280 -246.38%
2007 -5.100.555 96.09%
2008 -9.170.965 44.38%
2009 -6.635.708 -38.21%
2010 -5.869.417 -13.06%
2011 -6.580.953 10.81%
2012 -4.821.175 -36.5%
2013 -5.224.761 7.72%
2014 -10.978.008 52.41%
2015 -5.280.761 -107.89%
2016 -3.784.852 -39.52%
2017 -3.063.900 -23.53%
2018 -3.963.500 22.7%
2019 -9.501.340 58.28%
2020 -7.250.555 -31.04%
2020 -9.452.260 23.29%
2021 -12.082.320 21.77%
2022 -7.067.750 -70.95%
2023 -6.274.570 -12.64%
2024 -17.414.520 63.97%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Respiri Limited Gross Profit
Year Gross Profit Growth
1997 1.741.899
1998 0 0%
1999 0 0%
2000 0 0%
2001 -4.768.657.000 100%
2002 -2.537.000 -187864.41%
2003 -178.663 -1319.99%
2004 0 0%
2005 51.911 100%
2006 33.571 -54.63%
2007 325.944 89.7%
2008 100.191 -225.32%
2009 -69.522 244.11%
2010 78.607 188.44%
2011 92.317 14.85%
2012 32.008 -188.42%
2013 -142.135 122.52%
2014 18.975 849.06%
2015 93.988 79.81%
2016 -686.178 113.7%
2017 530.635 229.31%
2018 736.007 27.9%
2019 1.021.624 27.96%
2020 0 0%
2020 2.144.927 100%
2021 -2.259.751 194.92%
2022 -1.896.772 -19.14%
2023 -2.446.321 22.46%
2024 1.237.864 297.62%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Respiri Limited Net Profit
Year Net Profit Growth
1997 256.083
1998 -311.032 182.33%
1999 -912.093 65.9%
2000 -6.095.000 85.04%
2001 -8.695.000 29.9%
2002 -11.863.000 26.7%
2003 -4.293.067 -176.33%
2004 -225.446 -1804.26%
2005 -724.190 68.87%
2006 -1.227.244 40.99%
2007 -5.127.136 76.06%
2008 -11.678.053 56.1%
2009 -6.701.092 -74.27%
2010 -5.939.761 -12.82%
2011 -6.677.311 11.05%
2012 -5.585.172 -19.55%
2013 -5.583.649 -0.03%
2014 -10.309.957 45.84%
2015 -5.464.443 -88.67%
2016 -4.010.944 -36.24%
2017 -2.522.052 -59.03%
2018 -3.207.220 21.36%
2019 -8.474.586 62.15%
2020 -7.260.935 -16.71%
2020 -7.260.935 0%
2021 -11.040.347 34.23%
2022 -6.624.313 -66.66%
2023 -5.775.290 -14.7%
2024 -16.994.664 66.02%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Respiri Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1997 4
1998 -5 200%
1999 -15 71.43%
2000 -126 88.89%
2001 -89 -43.18%
2002 -165 46.34%
2003 -58 -182.76%
2004 0 0%
2005 0 0%
2006 0 0%
2007 -1 0%
2008 -1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 -2 100%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Respiri Limited Free Cashflow
Year Free Cashflow Growth
1997 148.432
1998 -5.032 3049.76%
1999 -22.511 77.65%
2000 -217.000 89.63%
2001 -10.240.755 97.88%
2002 -11.362.866 9.88%
2003 0 0%
2004 -620.942 100%
2005 -800.246 22.41%
2006 -657.469 -21.72%
2007 -2.480.032 73.49%
2008 -5.921.901 58.12%
2009 -3.507.687 -68.83%
2010 -5.281.476 33.59%
2011 -5.379.965 1.83%
2012 -4.882.257 -10.19%
2013 -4.952.897 1.43%
2014 -9.169.707 45.99%
2015 -5.909.289 -55.17%
2016 -2.407.686 -145.43%
2017 -2.928.006 17.77%
2018 -2.084.910 -40.44%
2019 -6.414.503 67.5%
2020 -4.700.819 -36.46%
2021 -7.393.349 36.42%
2022 -8.479.847 12.81%
2023 -4.511.987 -87.94%
2024 -3.345.925 -34.85%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Respiri Limited Operating Cashflow
Year Operating Cashflow Growth
1997 150.837
1998 0 0%
1999 0 0%
2000 0 0%
2001 -9.171.755 100%
2002 -11.179.866 17.96%
2003 0 0%
2004 -620.942 100%
2005 -798.419 22.23%
2006 -656.614 -21.6%
2007 -2.288.184 71.3%
2008 -5.800.146 60.55%
2009 -3.495.817 -65.92%
2010 -5.121.535 31.74%
2011 -5.353.963 4.34%
2012 -4.879.977 -9.71%
2013 -4.935.301 1.12%
2014 -9.098.240 45.76%
2015 -5.891.940 -54.42%
2016 -2.389.299 -146.6%
2017 -2.927.424 18.38%
2018 -2.077.008 -40.94%
2019 -6.411.324 67.6%
2020 -4.687.956 -36.76%
2021 -7.339.097 36.12%
2022 -8.477.582 13.43%
2023 -4.490.186 -88.8%
2024 -3.356.032 -33.79%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Respiri Limited Capital Expenditure
Year Capital Expenditure Growth
1997 2.405
1998 5.032 52.21%
1999 22.511 77.65%
2000 217.000 89.63%
2001 1.069.000 79.7%
2002 183.000 -484.15%
2003 0 0%
2004 0 0%
2005 1.827 100%
2006 855 -113.68%
2007 191.848 99.55%
2008 121.755 -57.57%
2009 11.870 -925.74%
2010 159.941 92.58%
2011 26.002 -515.11%
2012 2.280 -1040.44%
2013 17.596 87.04%
2014 71.467 75.38%
2015 17.349 -311.94%
2016 18.387 5.65%
2017 582 -3059.28%
2018 7.902 92.63%
2019 3.179 -148.57%
2020 12.863 75.29%
2021 54.252 76.29%
2022 2.265 -2295.23%
2023 21.801 89.61%
2024 -10.107 315.7%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Respiri Limited Equity
Year Equity Growth
1997 0
1998 0 0%
1999 15.940.983 100%
2000 7.596.502 -109.85%
2001 13.280.760 42.8%
2002 1.379.789 -862.52%
2003 -949.924 245.25%
2004 1.142.262 183.16%
2005 1.511.162 24.41%
2006 388.369 -289.1%
2007 2.405.630 83.86%
2008 4.852.716 50.43%
2009 3.929.387 -23.5%
2010 2.866.724 -37.07%
2011 2.109.796 -35.88%
2012 2.114.439 0.22%
2013 1.622.417 -30.33%
2014 9.076.405 82.12%
2015 3.900.397 -132.7%
2016 4.035.941 3.36%
2017 1.797.583 -124.52%
2018 1.650.813 -8.89%
2019 -1.562.704 205.64%
2020 2.494.776 162.64%
2021 7.570.162 67.04%
2022 3.007.787 -151.69%
2023 826.890 -263.75%
2024 2.636.940 68.64%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Respiri Limited Assets
Year Assets Growth
1997 0
1998 0 0%
1999 17.062.028 100%
2000 10.311.186 -65.47%
2001 14.879.479 30.7%
2002 2.538.202 -486.22%
2003 559.536 -353.63%
2004 1.304.953 57.12%
2005 1.592.147 18.04%
2006 422.385 -276.94%
2007 3.052.385 86.16%
2008 5.767.632 47.08%
2009 5.101.456 -13.06%
2010 4.595.092 -11.02%
2011 3.353.518 -37.02%
2012 3.112.830 -7.73%
2013 2.837.756 -9.69%
2014 10.604.209 73.24%
2015 5.184.960 -104.52%
2016 5.078.201 -2.1%
2017 2.641.238 -92.27%
2018 2.660.959 0.74%
2019 1.013.605 -162.52%
2020 4.618.904 78.06%
2021 9.107.572 49.29%
2022 4.205.349 -116.57%
2023 3.181.316 -32.19%
2024 6.190.916 48.61%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Respiri Limited Liabilities
Year Liabilities Growth
1997 0
1998 0 0%
1999 1.121.045 100%
2000 2.714.684 58.7%
2001 1.598.719 -69.8%
2002 1.158.413 -38.01%
2003 1.509.460 23.26%
2004 162.691 -827.81%
2005 80.985 -100.89%
2006 34.016 -138.08%
2007 646.755 94.74%
2008 914.916 29.31%
2009 1.172.069 21.94%
2010 1.728.368 32.19%
2011 1.243.722 -38.97%
2012 998.391 -24.57%
2013 1.215.339 17.85%
2014 1.527.804 20.45%
2015 1.284.563 -18.94%
2016 1.042.260 -23.25%
2017 843.655 -23.54%
2018 1.010.146 16.48%
2019 2.576.309 60.79%
2020 2.124.128 -21.29%
2021 1.537.410 -38.16%
2022 1.197.562 -28.38%
2023 2.354.426 49.14%
2024 3.553.976 33.75%

Respiri Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.01
Price to Earning Ratio
-6.31x
Price To Sales Ratio
113.02x
POCF Ratio
-7.07
PFCF Ratio
-7.78
Price to Book Ratio
17.81
EV to Sales
111.6
EV Over EBITDA
-6.4
EV to Operating CashFlow
-7.68
EV to FreeCashFlow
-7.68
Earnings Yield
-0.16
FreeCashFlow Yield
-0.13
Market Cap
0,05 Bil.
Enterprise Value
0,05 Bil.
Graham Number
0.02
Graham NetNet
-0

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
0.89
ROE
-2.41
Return On Assets
-1.2
Return On Capital Employed
-2.92
Net Income per EBT
0.93
EBT Per Ebit
0.99
Ebit per Revenue
-17.64
Effective Tax Rate
0.07

Margins

Sales, General, & Administrative to Revenue
2.78
Research & Developement to Revenue
0.3
Stock Based Compensation to Revenue
0.21
Gross Profit Margin
-3.59
Operating Profit Margin
-17.64
Pretax Profit Margin
-17.47
Net Profit Margin
-16.27

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-2.79
Return on Tangible Assets
-1.2
Days Sales Outstanding
202.22
Days Payables Outstanding
337.08
Days of Inventory on Hand
478.73
Receivables Turnover
1.81
Payables Turnover
1.08
Inventory Turnover
0.76
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0.02
Debt to Assets
0.01
Net Debt to EBITDA
0.08
Current Ratio
1.18
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
725329
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
2068703.5
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Respiri Limited Dividends
Year Dividends Growth

Respiri Limited Profile

About Respiri Limited

Respiri Limited, an e-health SaaS company, researches, develops, and commercializes medical devices in Australia. The company develops, produces, and sells mobile health applications. Its products include wheezo, an electronic wheeze detection tool to detect wheeze in children; respiri mobile application; and Respiri health portal. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. Respiri Limited is based in Melbourne, Australia.

CEO
Mr. Marjan Mikel B.Sc., M.A.I
Employee
2
Address
432 St Kilda Road
Melbourne, 3004

Respiri Limited Executives & BODs

Respiri Limited Executives & BODs
# Name Age
1 Mr. Nicholas Smedley
Executive Chairman
70
2 Mr. Marjan Mikel B.Sc., M.A.I.C.D.
Chief Executive Officer, MD & Executive Director
70
3 Dr. Samaneh Sarraf Shirazi
Chief Research Officer
70
4 Mr. William Sigsbee
Head of US Operations & Chief Commercial Officer for the US market
70
5 Mr. Justin Mouchacca B.Bus (Acc), C.A., CA
Joint Company Secretary
70
6 Ms. Nova Anne Taylor
Joint Company Secretary
70
7 Mr. Peter Hildebrandt
Chief Operations Officer
70
8 Prof. Noam Gavriely
Medical & Scientific Advisor
70
9 Mr. George Vlachodimitropoulos
Chief Technology Officer
70
10 Mr. Theo Antonopoulos
Chief Commercial Officer
70

Respiri Limited Competitors

Micro-X Limited Logo
Micro-X Limited

MX1.AX

(0.8)
Uscom Limited Logo
Uscom Limited

UCM.AX

(1.0)